GRTS
- Gritstone bio, Inc.
()
Overview
Company Summary
Gritstone bio, Inc. is a biotechnology company focused on developing personalized cancer immunotherapies. The company aims to harness the power of the immune system to identify and target tumor-specific neoantigens, which are unique markers present on cancer cells. By leveraging computational algorithms and advanced genomics, Gritstone bio aims to predict and design neoantigens that can induce a potent immune response against the tumor.
Gritstone bio's approach involves collecting and sequencing a patient's tumor DNA and RNA to identify the neoantigens specific to their cancer. This information is then used to create a personalized vaccine or cell therapy that trains the immune system to recognize and attack the cancer cells bearing these specific markers. The company's focus is on solid tumors, such as lung, prostate, breast, and colorectal cancers.
Through its expertise in genomics, machine learning, and immunology, Gritstone bio aims to develop innovative and effective immunotherapies that have the potential to improve patient outcomes. The company's ultimate goal is to provide personalized treatments that can significantly enhance the efficacy of cancer therapies while reducing the potential for side effects.